Catalyst [CPRX] vs Praxis Precision [PRAX] Detailed Stock Comparison

Catalyst Pharmaceuticals Inc.

NASDAQ
Loading...

Praxis Precision Medicines Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Catalyst Pharmaceuticals Inc. wins in 11 metrics, Praxis Precision Medicines Inc. wins in 3 metrics, with 0 ties. Catalyst Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Catalyst Pharmaceuticals Inc. Praxis Precision Medicines Inc. Better
P/E Ratio (TTM) 15.26 N/A N/A
Price-to-Book Ratio 3.29 9.46 Catalyst Pharmaceuticals Inc.
Debt-to-Equity Ratio 0.29 0.01 Praxis Precision Medicines Inc.
PEG Ratio -1.79 -38.31 Catalyst Pharmaceuticals Inc.
EV/EBITDA 8.20 -26.32 Catalyst Pharmaceuticals Inc.
Profit Margin (TTM) 36.39% 0.00% Catalyst Pharmaceuticals Inc.
Operating Margin (TTM) 40.53% 0.00% Catalyst Pharmaceuticals Inc.
EBITDA Margin (TTM) 40.53% N/A N/A
Return on Equity 25.49% -45.83% Catalyst Pharmaceuticals Inc.
Return on Assets (TTM) 16.48% -28.69% Catalyst Pharmaceuticals Inc.
Free Cash Flow (TTM) $208.61M $-249.12M Catalyst Pharmaceuticals Inc.
1-Year Return 25.12% 807.83% Praxis Precision Medicines Inc.
Price-to-Sales Ratio (TTM) 5.35 N/A N/A
Enterprise Value $2.42B $8.58B Praxis Precision Medicines Inc.
EV/Revenue Ratio 4.12 N/A N/A
Gross Profit Margin (TTM) 82.91% N/A N/A
Revenue per Share (TTM) $5 N/A N/A
Earnings per Share (Diluted) $1.68 $-13.48 Catalyst Pharmaceuticals Inc.
Beta (Stock Volatility) 0.66 2.97 Catalyst Pharmaceuticals Inc.
Short % of Float 9.56% 14.21% Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc. vs Praxis Precision Medicines Inc. Stock Performance Analysis

Loading Price Chart...

CPRX
PRAX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Catalyst Pharmaceuticals Inc.0.03%-0.19%8.05%30.95%38.24%35.08%
Praxis Precision Medicines Inc.8.08%-26.51%-23.68%-22.06%43.85%-10.03%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Catalyst Pharmaceuticals Inc.25.12%170.39%469.89%5,019.67%1,737.06%408.63%
Praxis Precision Medicines Inc.807.83%2,210.03%21.08%-16.07%-16.07%-16.07%

Performance & Financial Health Analysis: Catalyst Pharmaceuticals Inc. vs Praxis Precision Medicines Inc.

MetricCPRXPRAX
Market Information
Market Cap i$3.40B$9.60B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,486,945391,453
90 Day Avg. Volume i1,228,545416,321
Last Close$31.28$278.93
52 Week Range$19.05 - $32.56$37.19 - $366.52
% from 52W High-3.93%-23.90%
All-Time High$31.36 (May 21, 2026)$914.27 (Jan 04, 2021)
% from All-Time High-0.26%-69.49%
Growth Metrics
Quarterly Revenue Growth0.08%N/A
Quarterly Earnings Growth-0.06%-1.00%
Financial Health
Profit Margin (TTM) i0.36%0.00%
Operating Margin (TTM) i0.41%0.00%
Return on Equity (TTM) i0.25%-0.46%
Debt to Equity (MRQ) i0.290.01
Cash & Liquidity
Book Value per Share (MRQ)$7.79$34.85
Cash per Share (MRQ)$5.81$21.52
Operating Cash Flow (TTM) i$208.67M$-249,068,000
Levered Free Cash Flow (TTM) i$171.34M$-146,253,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Catalyst Pharmaceuticals Inc. vs Praxis Precision Medicines Inc.

MetricCPRX (Apr 24, 2026)PRAX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i15.26N/A
Forward P/E i8.23-38.31
PEG Ratio i-1.79-38.31
Price to Sales (TTM) i5.35N/A
Price to Book (MRQ) i3.299.46
Market Capitalization
Market Capitalization i$3.40B$9.60B
Enterprise Value i$2.42B$8.58B
Enterprise Value Metrics
Enterprise to Revenue i4.12N/A
Enterprise to EBITDA i8.20-26.32
Risk & Other Metrics
Beta i0.662.97
Book Value per Share (MRQ) i$7.79$34.85

Financial Statements Comparison: Catalyst Pharmaceuticals Inc. vs Praxis Precision Medicines Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCPRX (2025)PRAX (2025)
Revenue/Sales i588.99M0
Cost of Goods Sold i87.25MN/A
COGS % of Revenue i14.8%-
Gross Profit i501.74MN/A
Gross Margin i85.2%-
Research & Development i12.71M267.12M
Operating Income (EBIT) i257.78M-326.20M
Operating Margin i43.8%-
EBITDA i294.68M-326.06M
EBITDA Margin i50.0%-
Pre-Tax Income i283.52M-303.27M
Pre-Tax Income % of Revenue i48.1%-
Income Tax i69.19MN/A
Income Tax % of Revenue i11.7%-
Net Income (Profit) i214.33M-303.27M
Profit Margin i36.4%-

Balance Sheet & Liquidity Metrics

MetricCPRX (2025)PRAX (2025)
Cash & Equivalents i709.17M357.33M
Total Current Assets i894.03M610.91M
Total Current Assets % of Revenue i151.8%-
Total Current Liabilities i147.15M59.77M
Total Current Liabilities % of Revenue i25.0%-
Long-Term Debt i2.35M0
Long-Term Debt % of Revenue i0.4%-
Total Shareholders Equity i954.27M878.14M
Retained Earnings i474.19M-1.14B
Retained Earnings % of Revenue i80.5%-
Property, Plant & Equipment i1.94M415,000

Cash Flow Statement Comparison

MetricCPRX (2025)PRAX (2025)
Operating Cash Flow i185.19M-257.32M
Operating Cash Flow % of Revenue i31.4%-
Capital Expenditures i-58,000-56,000
Free Cash Flow i208.61M-249.12M
FCF Margin i35.4%-
Debt Repayment iN/AN/A
Common Stock Repurchase i-25.30MN/A

Short Interest & Institutional Ownership Analysis

MetricCPRXPRAX
Shares Short i9.13M3.95M
Short Ratio i7.679.07
Short % of Float i9.56%14.21%
Shares Outstanding i122.51M25.20M
Float Shares i114.53M25.78M
% Held by Insiders i6.19%0.40%
% Held by Institutions i89.21%106.12%
% Held by Public i4.60%-6.52%

Dividend Analysis & Yield Comparison: Catalyst Pharmaceuticals Inc. vs Praxis Precision Medicines Inc.

MetricCPRXPRAX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A